These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 36365206)

  • 21. High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed
    Wijaya YOS; Niba ETE; Nishio H; Okamoto K; Awano H; Saito T; Takeshima Y; Shinohara M
    Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antisense therapies in neurological diseases.
    Brunet de Courssou JB; Durr A; Adams D; Corvol JC; Mariani LL
    Brain; 2022 Apr; 145(3):816-831. PubMed ID: 35286370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Chemically Modified Nucleic Acid Analogues for Splice Switching Application.
    Le BT; Chen S; Veedu RN
    ACS Omega; 2023 Dec; 8(51):48650-48661. PubMed ID: 38162739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides.
    Dastpeyman M; Sharifi R; Amin A; Karas JA; Cuic B; Pan Y; Nicolazzo JA; Turner BJ; Shabanpoor F
    Int J Pharm; 2021 Apr; 599():120398. PubMed ID: 33640427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of nucleobase chemical modifications that reduce the hepatotoxicity of gapmer antisense oligonucleotides.
    Yoshida T; Morihiro K; Naito Y; Mikami A; Kasahara Y; Inoue T; Obika S
    Nucleic Acids Res; 2022 Jul; 50(13):7224-7234. PubMed ID: 35801870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
    Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
    Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The powerful world of antisense oligonucleotides: From bench to bedside.
    Quemener AM; Bachelot L; Forestier A; Donnou-Fournet E; Gilot D; Galibert MD
    Wiley Interdiscip Rev RNA; 2020 Sep; 11(5):e1594. PubMed ID: 32233021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
    Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recent progress and prospect in oligonucleotide therapeutics].
    Yoshioka K; Kuwahara H; Nishina K; Nagata T; Yokota T
    Nihon Rinsho; 2015 Jun; 73(6):1057-65. PubMed ID: 26065142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RNA therapeutics: RNAi and antisense mechanisms and clinical applications.
    Chery J
    Postdoc J; 2016 Jul; 4(7):35-50. PubMed ID: 27570789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
    Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
    J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.
    Chen S; Heendeniya SN; Le BT; Rahimizadeh K; Rabiee N; Zahra QUA; Veedu RN
    BioDrugs; 2024 Mar; 38(2):177-203. PubMed ID: 38252341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
    Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
    Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antisense Drugs Make Sense for Neurological Diseases.
    Bennett CF; Kordasiewicz HB; Cleveland DW
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():831-852. PubMed ID: 33035446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modular Synthesis of Trifunctional Peptide-oligonucleotide Conjugates
    Dastpeyman M; Karas JA; Amin A; Turner BJ; Shabanpoor F
    Front Chem; 2021; 9():627329. PubMed ID: 33738276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1.
    De Serres-Bérard T; Ait Benichou S; Jauvin D; Boutjdir M; Puymirat J; Chahine M
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-sensitivity quantification of antisense oligonucleotides for pharmacokinetic characterization.
    Mahajan S; Zhao H; Kovacina K; Lachacz E; Hoxha S; Chan J; Liang M
    Bioanalysis; 2022 May; 14(9):603-613. PubMed ID: 35578971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antisense oligonucleotide-based therapies for the treatment of osteoarthritis: Opportunities and roadblocks.
    Nakamura A; Ali SA; Kapoor M
    Bone; 2020 Sep; 138():115461. PubMed ID: 32485363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic.
    Rook ME; Southwell AL
    BioDrugs; 2022 Mar; 36(2):105-119. PubMed ID: 35254632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy.
    Matsuo M
    JMA J; 2021 Jul; 4(3):232-240. PubMed ID: 34414317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.